Lexeo Therapeutics, Inc. (LXEO), a clinical-stage genetic medicine company pioneering novel treatments for cardiovascular diseases, has finalized the pivotal study design for gene therapy candidate LX2006 in Friedreich Ataxia.
The study, dubbed SUNRISE-FA 2, is an open-label pivotal study in which 13 participants aged 16 years and older will receive a single intravenous administration of high-dose LX2006 compared with 13 participants untreated with LX2006 (untreated control). The study does not include a placebo or sham procedure for participants in the untreated control arm.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.